UNSPSC 51202902: Defibrotide

This classification denotes an immunosuppessant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 438HCF2X0M, chemically known as sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from bovine lung dna. European Medicines Agency schedules defibrotide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01572MIG. Most nations, for tariff and trade purposes, schedule Defibrotide under HS 30012090 and SITC 54162. SMILES:.

Defibrotide bears US NLM identifiers UMLS ID C0057257 and NCI Concept Code C1064.

UNSPSC 51202902 Defibrotide is a Commodity code nominally identifying a specific pharmaceutical agent, but recent state and local activity under this code designation shows a substantial mismatch between the code's abstract scope and actual procurement activity. The opportunities posted under this code span medical and first aid supplies for emergency response, naloxone and drug deactivation systems for public health, generic pharmaceuticals and OTC products distributed through state cooperative purchasing, and direct-to-manufacturer prescription programs. State and local buyers under this code include county health departments, city fire departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work being solicited ranges from emergency medical consumables (respiratory equipment, cardiac monitoring devices, endotracheal tubes, bandaging materials, oxygen delivery systems) to pharmaceutical products supplied through licensed wholesalers to direct contracting arrangements between state pharmacy benefit programs and manufacturers outside traditional PBM and GPO channels.

Issuing bodies include Seminole County, Florida (county health), the City of Tampa (municipal fire department), the Texas Health and Human Services Commission (state agency), and the Minnesota Department of Administration through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which also serves Oregon participants. Recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, due July 26, 2023), the City of Tampa's ITB for medical and first aid supplies for the Fire Department Rescue Division (169 line items, estimated contract value $700,000.00, due March 13, 2026, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount), MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (proposals due March 26, 2026, effective July 1, 2026, through three authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson), and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026). The code shows activity concentrated in Florida, Texas, and the Minnesota/multistate cooperative region, though the divergence between the code's nominal scope and the diverse pharmaceutical and medical supply work actually being solicited suggests either mis-tagging of opportunities or use of the code as a catch-all for healthcare product procurement across multiple categories.